Sansure BiotechSHSE:688289 -3.90%62 Gross Margin % is 73.31% as of Mar. 2026, which is 2% above its 10-year median of 71.54. GuruFocus rates SHSE:688289 with a GF Score™ of 62/100 and a GF Value™ of ¥20.69 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Sansure Biotech ranks better than 85.59% on this metric.
The historical rank and industry rank for Sansure Biotech's Gross Margin % or its related term are showing as below:
SHSE:688289'
s Gross Margin % Range Over the Past 10 Years
Min: 49.81 Med: 71.54 Max: 79.64
Current: 74.84
During the past 9 years, the highestGross Margin % of Sansure Biotech was 79.64%. The lowest was 49.81%. And the median was 71.54%.
SHSE:688289's Gross Margin % is ranked better than 85.59% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.03
vs SHSE:688289: 74.84
Sansure Biotech had a gross margin of 73.31% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sansure Biotech was 0.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sansure Biotech had a gross margin of 73.31% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sansure Biotech Gross Margin % Related Terms
Sansure Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sansure Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688289 vs ISRG, BDX, MDLN: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sansure Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sansure Biotech Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sansure Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sansure Biotech (SHSE:688289) has a Gross Margin % of 73.31% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Sansure Biotech and its competitors. This is near median its historical median of 71.54. Over the past decade, Sansure Biotech's Gross Margin % has ranged from 49.81 to 79.64. According to the industry distribution chart, Sansure Biotech ranks #116 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 14.4%.
Is Sansure Biotech's Gross Margin % too high?
Sansure Biotech's current Gross Margin % of 73.31% is near median its 10-year median of 71.54. Over the past 10 years, this metric has ranged from a low of 49.81 to a high of 79.64. The Medical Devices & Instruments industry median Gross Margin % is 52.03. Sansure Biotech's value of 73.31% is 40.9% above this industry median. Based on the distribution chart, Sansure Biotech ranks #116 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sansure Biotech has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sansure Biotech ranks #116 out of 805 companies for Gross Margin %. This places Sansure Biotech in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.03. Sansure Biotech's value of 73.31% is 40.9% above this benchmark. Historically, Sansure Biotech's own Gross Margin % has ranged from 49.81 to 79.64 over the past decade. While the company's 10-year median is 71.54 vs. the industry median of 52.03, Sansure Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.03, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sansure Biotech's current Gross Margin % of 73.31% is 40.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sansure Biotech and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sansure Biotech's current Gross Margin % is 73.31%, which is near median its own 10-year median of 71.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.69, compared to a current price of ¥14.54 — trading 29.7% below its estimated fair value. The current Gross Margin % is 73.31%, which is near median its 10-year median of 71.54 and 40.9% above the Medical Devices & Instruments industry median of 52.03. Sansure Biotech's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Gross Margin % is 73.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sansure Biotech (SHSE:688289) Overvalued in 2026?
Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued.
The current stock price of ¥14.54 is trading 29.7% below its estimated GF Value™ of ¥20.69.
GuruFocus considers Sansure Biotech to be Possible Value Trap.
Key valuation signals for SHSE:688289:
Gross Margin %: 73.31% (near median its 10-year median of 71.54)
GF Value™: ¥20.69 vs. price of ¥14.54 (29.7% below fair value)
Industry Position: 40.9% above the Medical Devices & Instruments median (#116 of 805)
No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688289 has been successfully added to your 
